-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shisi Pharmaceutical Group Ranks Among the Top 25 on the Hong Kong Stock Exchange’s Top 100 Pharmaceutical List
Category:
发布时间：2023-02-25
【概要描述】
On February 24, at the “Digital Transformation, Co-Creating New Value” 2022 Hong Kong Listed Companies Development Summit and the 10th “Top 100 Hong Kong Stocks” Awards Ceremony—hosted by the Top 100 Hong Kong Stocks Research Center and co-organized by Caihua Society, Futu AnYi, and Dongshi Technology—Shisi Pharmaceutical Group was honored as one of the Top 25 on the Top 100 Hong Kong Stocks Pharmaceutical List.
On February 24, at the “Digital Transformation, Co-Creating New Value” 2022 Hong Kong Listed Companies Development Summit and the 10th “Top 100 Hong Kong Stocks” Awards Ceremony—hosted by the Top 100 Hong Kong Stocks Research Center and co-organized by Caihua Society, Futu AnYi, and Dongshi Technology—Shisi Pharmaceutical Group was honored as one of the Top 25 on the Top 100 Hong Kong Stocks Pharmaceutical List.
As one of the backbone enterprises in China’s pharmaceutical industry, Shisi Pharmaceutical Group has seized the development opportunities arising from shifts in the industry landscape and market dynamics. Focusing on both domestic and international dual circulation, the company is intensifying its innovation-chain deployment and product-development efforts across key areas such as specialty generic drugs, active pharmaceutical ingredients, innovative medicines, and pharmaceutical packaging materials. These initiatives have effectively optimized the product mix and enhanced the quality and efficiency of growth, earning widespread recognition and attention from both the product market and capital markets through outstanding performance.
The “Top 100 Hong Kong Stocks” selection initiative was launched in 2012 by Tencent.com and Caihua News Agency. Each year, the program employs rigorous data and a comprehensive set of scientifically sound evaluation criteria to identify outstanding Hong Kong–listed companies, publish a ranking list, and present awards. The initiative aims to recognize well-performing, investment-worthy listed firms on the Main Board of the Hong Kong Stock Exchange, thereby fostering the healthy and robust development of Hong Kong’s capital market. In addition, the event integrates a high-level summit forum with an awards ceremony for listed companies, providing a platform for discussing financial market dynamics and economic trends. With steadily growing attendance and increasing support from key institutions, the event’s influence has expanded year after year, establishing itself as one of the annual flagship events in Hong Kong’s finance and business communities.
According to reports, the “Top 100 Hong Kong Stocks” initiative has consistently aimed to establish a prestigious and credible ranking of Hong Kong-listed companies, guided by the principles of professionalism, objectivity, impartiality, and accuracy. Through a rigorous selection panel, seasoned advisory expertise, in-depth professional analysis, and a fair, impartial, and trustworthy evaluation process, the initiative identifies outstanding Hong Kong-listed firms, thereby setting new benchmarks for investors. The objectivity of the selection results is widely recognized and trusted by professional institutions and investors alike.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091